

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

pMSCVpuro-Flag-cMyc T58A

RRID:Addgene_20076

Type: Plasmid

Proper Citation

RRID:Addgene_20076

Plasmid Information

URL: <http://www.addgene.org/20076>

Proper Citation: RRID:Addgene_20076

Insert Name: cMyc

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:18931654](#)

Vector Backbone Description: Backbone Marker:Clontech; Backbone Size:6300; Vector Backbone:pMSCVpuro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: pMSCVpuro-Flag-cMyc T58A

Relevant Mutation: T58A

Record Creation Time: 20220422T222049+0000

Record Last Update: 20260815T081151+0000

Ratings and Alerts

No rating or validation information has been found for pMSCVpuro-Flag-cMyc T58A.

No alerts have been found for pMSCVpuro-Flag-cMyc T58A.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bristol JA, et al. (2024) Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice. PLoS pathogens, 20(4), e1012132.

Scarpa M, et al. (2021) PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3 β -Mediated c-Myc and Pim-1 Proteasomal Degradation. Molecular cancer therapeutics, 20(4), 676.

Scarpa M, et al. (2021) Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. Oncotarget, 12(18), 1763.

Yi J, et al. (2019) MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine, 43, 225.

Rockfield S, et al. (2019) Chronic iron exposure and c-Myc/H-ras-mediated transformation in fallopian tube cells alter the expression of EVI1, amplified at 3q26.2 in ovarian cancer. Oncogenesis, 8(9), 46.

Rockfield S, et al. (2018) Expression and function of nuclear receptor coactivator 4 isoforms in transformed endometriotic and malignant ovarian cells. Oncotarget, 9(4), 5344.

Vaseva AV, et al. (2018) KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer cell, 34(5), 807.

Liu P, et al. (2011) Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature medicine, 17(9), 1116.